A randomized phase ii, double-blind, multicenter study evaluating the efficacy and safety of autogene cevumeran plus nivolumab versus placebo plus nivolumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma

A personalised cancer vaccine is being tested alongside an immunotherapy drug to see if it can prevent bladder cancer from returning after surgery. This matters because muscle-invasive urothelial carcinoma (MIUC) has a high risk of recurrence even after the bladder is removed. Current standard care—nivolumab alone—reduces that risk but does not eliminate it. The problem is that each patient’s tumour has a unique genetic fingerprint, so a one-size-fits-all immune approach may miss some cancer cells. Autogene cevumeran is made specifically for each participant, designed to train the immune system to recognise and attack the distinctive mutations in their own tumour. If the combination proves more effective than nivolumab alone, it could shift the standard of care for high-risk MIUC. Instead of relying solely on a general immune checkpoint inhibitor, patients would receive a tailored vaccine that primes their immune system to hunt residual cancer cells. The study involves 23 participants in the UK and 362 worldwide, with treatment given over roughly 21 months. Success would mean fewer recurrences and longer survival for a patient group that currently has limited options after surgery.